Think your odds of R&D success are miserable? MIT’s Andrew Lo might have a surprise for you
Maybe the odds of success in a clinical trial aren’t as miserable as just about everyone in the biopharma R&D sector assumes.
MIT professor Andrew Lo and his team crunched the results on more than 185,000 clinical trials involving 21,000 compounds — courtesy of some new techniques in Big Data analysis — and found that nearly 14% of the drugs that make it to the clinic actually go on to an approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
